Will GLP-1s be able to prevent or treat Alzheimer's?

Ozempic and Alzheimer's disease: could the world's most talked-about weight loss drug also protect your brain?

In this episode of Blasphemous Nutrition we follow one of the most compelling and complicated questions in brain health and cognitive decline today. Aimee breaks down the hypothesis that Alzheimer's disease may be a metabolic brain disorder, explores the groundbreaking real-world data that launched two massive GLP-1 clinical trials, and walks through what happened when those trials delivered their verdict.

We also dig into the work of neurologist Dr. Dale Bredesen, whose ReCODE protocol research suggests Alzheimer's isn't one disease at all, but rather distinct subtypes including inflammatory, glycotoxic, toxic, and vascular Alzheimer's,  and how this changes everything about prevention and treatment.

Whether you're interested in GLP-1 receptor agonists, dementia prevention, metabolic health, or simply understanding your brain as you age, this episode connects the dots.

The science is messy. The stakes are high. And the story isn't over.

Other Brain Health Episodes:

Nutrition and Your Brain: Part 1 - Diet and Mental Health

Nutrition and Your Brain: Part 2 - What to Eat to Ease Depression and Anxiety

Nutrition and Your Brain: Part 3 - Preventing Dementia and Alzheimer’s

Protecting Your Brain Means Protecting Your Heart - Here’s What You Need for Both! 

CSI: Cortex — Lithium and Alzheimer’s Disease

Find Research Citations and Transcript at Blasphemous Nutrition on Substack

Work with Aimee

Photography by: Dai Ross Photography

Podcast Cover Art: Lilly Kate Creative

How to Leave a Review on Apple Podcasts
Via iOS Device
1.   Open Apple Podcast App (purple app icon that says Podcasts).
2.   Go to the icons at the bottom of the screen and choose “search”
3.   Search for “Blasphemous Nutrition”
4.   Click on the SHOW, not the episode.
5.   Scroll all the way down to “Ratings and Reviews” section
6.   Click on “Write a Review” (if you don’t see that option, click on “See All” first)
7.   Rate the show on a five-star scale (5 is highest rating) and write a review!
8.   Bask in the glow of doing a good deed that makes a difference!

Transcript

0:02

The data looked extraordinary. The biology made sense. The animal studies were compelling, and the observational evidence was the strongest anyone has seen in years. Then they ran the trial. Today's episode is about what happened next. Hey rebels, welcome to Blasphemous Nutrition. Consider this podcast your pantry full of clarity, perspective, and the nuance needed to counter the superficial health advice so freely given on the internet. I'm Aimee, the unapologetically candid host of Blasphemous Nutrition, and a double-degreed nutritionist with twenty years experience. I'm here to share a more nuanced take on living and eating well to sustain and recover your health. If you've found most health advice to be so generic as to be meaningless or so extreme that it's unrealistic, and you don't mind the occasional F-bomb, you've come to the right place. From dissecting the latest nutrition trends to breaking down published research and sharing my own clinical experiences, I'm on a mission to foster clarity amidst all the confusion and empower you to have the health you need to live a life you love. Now let's get started Welcome back to Blasphemous Nutrition, darling. I am your host, Aimee, and Harvard offered me an honorary doctorate, which I declined because I felt they needed it more than I did. There has been much talk in the last year or so about our latest pharma darling, Ozempic, being potentially beneficial in preventing or reversing cognitive decline. Now, initially, I poo-pooed this as a PR stunt to further drive research, marketing, and use of these mega blockbuster drugs that Americans were rabidly fighting over to get themselves snatched for the summer, like they were parents in Toys R Us punching one another over a Cabbage Patch Kid at 9:00 AM the Friday after Thanksgiving in 1985. I mean, if I was in big pharma and having a wildly, unprecedentedly successful run of a drug, I'd wanna find all sorts of ways to extend the lifespan of that cash cow and create all sorts of new patents to keep that moolah rolling in. At the same time that Ozempic was taking the country by storm, we were having serious panic attacks about the prevalence of Alzheimer's disease and the fact that all of the research we've been doing and all of the drugs that we've created targeting amyloid plaque and tau proteins have produced shitty results. A whole generation of effort down the drain with hardly anything to show for it. But what really happened was a compelling observation that legitimately warrants looking deeper. In 2024, researchers harvested data from electronic health records of 116 million Americans and showed that those taking GLP-1 medications had a 40 to 70% lower risk for a first-time Alzheimer's diagnosis within three years. Now, you know better than to get carried away with observational data. You know that correlation is not causation. But when there is a signal that strong in a data set that large, it's not nothing. It's pretty bloody impressive any which way you slice it, and that is what led to conducting more research. Studies had already shown that GLP-1s do cross the blood-brain barrier, And animal model studies indicated a neuroprotective effect, preventing memory impairment and synapse loss in mice with Alzheimer's. So let me go back a bit. I'm sure that everyone listening is well aware that GLP-1 medications are helpful for weight loss, and I imagine most of you also know that its original intended use was as a diabetes treatment. But unlike our other diabetes medications, this one works a little bit differently. GLP-1 stands for glucagon-like peptide one. Glucagon-like peptide one is a hormone that's naturally released in the intestines after you eat, signaling the pancreas to release insulin, slow down digestion, reduce appetite, and regulate blood sugar. Drugs like semaglutide, the active ingredient in both Ozempic and Wegovy, mimic this naturally occurring hormone. They bind to GLP-1 receptors throughout the body, and then those receptors create a cascade of events that lead to that lowered insulin, slowed digestion, reduced appetite, and so on. And this is what opened up the whole line of inquiry, because GLP-1 receptors are not only found in the gut and the pancreas. They're pretty much everywhere in the body, in the heart, kidneys, lungs, even the vagus nerve, but also in the brain. Most importantly, they're found in the hippocampus, which is the region critical for memory and learning, as well as in the prefrontal cortex and areas governing inflammation and cellular health. So scientists started asking, wisely, what happens when you activate those receptors? What are the consequences of a medication that has the capacity to alter receptor activity system-wide? I've been asking those questions myself And that's one of the reasons why I was a little hesitant about the GLP-1 bandwagon when it first started being accessible to everybody, right? But what they found in lab studies and animal models with regards to the brain was promising. A 2025 review published in the journal Receptors, don't you love it that they have a whole scientific journal dedicated to cell receptors? That's... The geek level on that is so fantastic. I love it. I think it's adorable. Anyway, this, uh, review published in the journal Receptors synthesized the preclinical and clinical evidence available and concluded, I'm quoting here, "Preclinical studies, both in vitro and in vivo," so both in Petri dishes and in living creatures, "have demonstrated promising neuroprotective effects, including reductions in amyloid beta accumulation, decreased tau hyperphosphorylation, improved synaptic plasticity, and enhanced neuronal survival." For decades, the dominant theory of Alzheimer's has been what's called the amyloid hypothesis, the idea that a protein called amyloid beta accumulates in the brain, which it does, forms plaques, and those plaques are the engine of the disease. That's the hypothesis, that the amyloid beta drives the disease. And so researchers were thinking, "If we kill off the plaques, if we get rid of the plaque, we'll save the brain." And this was the hypothesis that produced drug after drug, which usually failed, often spectacularly, in clinical trials. But damn if we weren't stuck on that notion and determined to beat that horse beyond dead until it was a bleached skeleton laying in the sand. Eventually, a growing number of researchers started asking a different question: what if amyloid isn't the cause? What if amyloid is the response? A kind of alarm signal that the brain is setting off because something else had already gone wrong. Dr. Dale Bredesen was one such researcher. Bredesen spent decades at UCLA studying the brain mechanisms of neurodegeneration, and he has concluded that Alzheimer's disease does not have one singular cause. It has multiple, each with its own underlying driver. Bredesen maps out these hypothesized causes into distinct biological subtypes. So I'm gonna go through these quickly because it does matter when it comes to this GLP-1 Alzheimer's hypothesis that's being played out in the research right now Type one is inflammatory. This subtype is driven by chronic systemic inflammation, the low-grade, persistent kind that smolders for years and only really shows up as elevated, highly sensitive C-reactive protein or interleukin-6 on labs. It's strongly associated with the APOE4 gene variant, which for those of you who are interested in Alzheimer's, you've probably heard of that. It is the most significant known genetic risk factor for Alzheimer's disease. Now, when inflammation goes uncontrolled, it damages neurons, it disrupts brain signaling, and it creates an environment where amyloid can accumulate, not as the cause, but as the brain's defensive response to the damage being done. You can think of amyloid plaque on the neurons as being the brain's equivalent atherosclerotic plaque on the arteries in the heart, okay? It's kind of A similar situation going on. There's another type called type 1.5, and that is called the glycotoxic type. Now, our brain runs almost exclusively on glucose, and it requires a lot of it. I suspect that's why our liver is able to produce glucose in the absence of any dietary source of glucose, right, or carbohydrate. Now, a glucose-deprived brain is an energy-deprived brain. The brain also requires insulin signaling in order to use that glucose properly. When someone develops insulin resistance, be it from a poor diet, metabolic dysfunction, or genetics, the brain starts to lose that signaling. It becomes starved of fuel even though there's plenty of fuel available for it This subtype has actually been called type 3 diabetes by some researchers and functional medicine practitioners because the brain, like peripheral tissue, becomes insulin resistant. And if the brain is insulin resistant, a drug that improves insulin sensitivity, like a GLP-1 agonist, might actually help. Type 3 is atrophic Alzheimer's subset, and this subtype is driven by insufficiency, specifically a lack of the trophic factors that the brain needs to maintain and repair itself. These include hormones like insulin itself, thyroid hormone, sex hormones, including estrogen and testosterone. When the brain is deprived of these hormonal signals, neurons begin to atrophy. It often occurs through aging, menopause, or hormonal disruption, which is why historically Alzheimer's has been a disease of more elderly folks Because it is a disease that takes 20 or 30 years in order for symptoms to show up, historically we would see people more in their 80s and later developing Alzheimer's. But as we all know, the age of onset is in some folks quite younger, and I'm gonna get to that in a moment. Type Three is toxic, and this subtype is associated with toxic exposure, such as heavy metals like mercury, lead, cadmium, biotoxins from chronic mold exposure, as well as environmental chemicals. What's interesting is that type three tends to strike younger people, those who are in their late forties to early sixties, and it doesn't usually begin with the memory loss that we typically associate with Alzheimer's. Instead, early symptoms involve difficulty with math, finding words, challenges reading or following complex rules and sequence. It often occurs in people who do not have the APOE4 gene, which means it doesn't run in families the same way, right? It's strictly an environmental exposure, and it can be missed or misdiagnosed for years. Type four is vascular-driven, and this subtype is rooted in compromised blood flow to the brain due to cardiovascular disease, hypertension, small vessel disease, or someone with a history of mini strokes. Without adequate blood supply, neurons don't get the oxygen and the nutrients that they need, and they die. This type is particularly relevant because it overlaps with other subtypes, and because vascular health interventions like exercise, blood pressure control, dietary change can also directly address it. So this is one reason why exercise has been confirmed time and time again as an effective Alzheimer's preventative in some, but not all cases. It preserves the vascular system, and it also delivers more oxygen to the brain. And then type five is traumatic. This is associated with head trauma, concussions, repeated impacts, traumatic brain injury, and connects to the well-documented link between contact sports like football, military service, or war veterans with later cognitive decline. The mechanism involves inflammation in the brain called neuroinflammation that's triggered by that physical injury, and it never has a chance to fully resolve. So it overlaps a little bit with type one, but it may not have those early indications on the lab if the inflammation itself is confined solely to the brain. Now, it's important that I mention Bredesen's framework of these five different subtypes of Alzheimer's disease is not a universally accepted hypothesis in the mainstream Alzheimer's research community. It has generated controversy, and the clinical evidence base for his protocol, called ReCODE, is still in development. But I will tell you, that protocol does show a hell of a lot more promise than many of those anti-amyloid drugs did. His underlying principle is that Alzheimer's is a disease that has multiple pathological drivers that are gaining traction within the broader community, and eventually, this is going to have profound implications for how we design and interpret drug trials. I think what we're seeing with this interest in GLP-1 medications for Alzheimer's treatment is actually reflective of that Okay, so let's go back to how things have progressed with that GLP-1 research path with regards to Alzheimer's. By the early 2020s, researchers had animal model data showing neuroprotective effects of GLP-1 agonists. They had mechanistic theory. And then in October 2024, that promising observational signal that we got, that researchers saw amongst all of those millions of Americans, got a lot of folks excited. Dr. Rong Xu and colleagues at Case Western Reserve School of Medicine published their observations in the journal Alzheimer's Dementia. It was a target trial emulation, meaning that rather than running a randomized controlled trial, which takes years and a massive amount of financial resources, the researchers used a national database of electronic health records from one hundred and sixteen million Americans to simulate seven different clinical trials. They identified more than a million eligible patients who had Type 2 diabetes and were sixty and older, who had no prior Alzheimer's diagnosis, and compared those starting semaglutide to those starting several other classes of anti-diabetic medications, and then tracked who got an Alzheimer's diagnosis over the following three years. And this is where they found that semaglutide was associated with a forty to seventy percent lower risk of first-time Alzheimer's diagnosis compared to the other medications, with the strongest effect of seventy percent reduction seen against those taking insulin, and a non-trivial reduction of forty percent risk when compared to those on other GLP-1 drugs. More recently, real-world data from the Cleveland Clinic researchers, published in the journal Alzheimer's Dementia again in twenty twenty-five, found that patients with type two diabetes who started GLP-1 agonists did have a significantly lower risk of Alzheimer's compared to patients starting a different class of diabetes drugs called DPP-4 inhibitors. So again, despite showing so much promise, these studies do have significant limitations. The SHU study, despite its enormous size, is observational. So the patient groups may not have been fully comparable. People prescribed semaglutide might differ from those who were prescribed insulin or metformin in ways that you can't actually tease out just looking at health records. There's also a concern about early diagnoses skewing results. If some patients were already in early undetected stages of Alzheimer's when they started a different medication, that could make semaglutide look more protective than it actually is. The authors of this paper themselves were very careful to say this study doesn't prove causation, only association. Good on them for spelling that out, 'cause it's really damn important. These questions and these unknowns are exactly the reason why a rigorous randomized controlled trial is needed, and that is what these trials are specifically designed to answer So here we have a situation where the epidemiological case is building, the animal models that existed before that support it, mechanisms seem highly plausible, and so the makers of Ozempic and Wegovy, Novo Nordisk, made a decision that was not based solely in milking profits, as my jaded psyche initially surmised. Novo Nordisk launched two phase three clinical trials. Now, a phase three clinical trials, this is big league, requires thousands of patients, hundreds of millions of dollars, and years of commitment from everyone, from research participants to the scientists, right? This is the stage where drugs either earn their green light or they're tossed aside. These trials were called EVOKE and EVOKE Plus. They are global, multi-center, randomized, double-blind, placebo-controlled studies, the sexy gold standard of clinical research. And for a double-blind, placebo-controlled study, they were genuinely large. Between May 2021 and September 2023, almost 4,000 participants across nearly 40 countries were enrolled in EVOKE and EVOKE Plus. Now, these two trials were nearly identical in design. There was one critical distinction. Inclusion criteria was the same for both, but one key difference determined which study they would be in. EVOKE excluded participants who had significant changes to the white matter in their brain. This is a marker of cerebrovascular disease and stroke risk. EVOKE Plus allowed a small proportion of participants who did have those changes to test whether the drug might also help people with some vascular component to their disease. Practically speaking, EVOKE Plus was designed to explore whether semaglutide's potential vascular and anti-inflammatory mechanisms could be beneficial for a population that has cerebrovascular disease layered on top of their Alzheimer's pathology. Those two disease states often coexist. So it was actually really smart and thoughtful of them to do this. Okay, let's talk more about these participants, because this matters. The average age of the participant was about 72. Roughly half of them were women. Good job, guys. I appreciate that. Just over three-quarters were white. They tested for the presence of amyloid in participants' brains via PET scan or cerebral fluid analysis, so researchers knew that they were dealing with genuine Alzheimer's pathology, not just aging or some other cause of memory problems. Cognitive scores taken by participants indicated they were in early stages of the disease, they had mild cognitive impairment or very mild dementia, and this is the window where if you're gonna intervene, you'll wanna be stepping in real quick-like, right? Between 55% and 60% of participants were already on Alzheimer's-specific medications, and here's the piece that's important. The proportion of participants with Type 2 diabetes was 13.6%. The vast majority of people in these trials did not have diabetes. They had Alzheimer's disease, confirmed amyloid positive, early stage Alzheimer's disease, but not generally, by and large, the insulin resistance and metabolic dysfunction that the original epidemiological signal came from Both trials ran for about three years. Participants also took oral semaglutide, not the injectable form, and they titrated up to 14 milligrams daily, which is the clinically relevant dose used for type 2 diabetes. The primary measure of success was whether the drug slowed the progression of cognitive decline. In November twenty twenty-five, Novo Nordisk announced their results. An analysis done by Nature Biotechnology summarized it bluntly, so I'm gonna let them speak for me, and I quote, "The first two clinical trials to look at the effect of glucagon-like peptide one agonists on Alzheimer's disease have delivered disappointing results. In November, Novo Nordisk announced the outcome of phase three studies testing GLP one weight loss drug Ozempic on Alzheimer's disease. Although the drugs have shown neuroprotective effects in animal models, those effects may not, as many hoped, extend to Alzheimer's disease as the medication did not slow disease progression." Novo Nordisk wisely discontinued their planned one-year extension of the trial based on those results. After years of investment and global enrollment, the answer was a very solid no. Now, most of the world is gonna see this as another failure and look elsewhere, but right there, right there in the data, not even well-hidden, right there in the data are some clues that bring up additional questions that I honestly think have answers readily available. A subset of participants in both trials underwent regular spinal fluid testing, what researchers call a CSF sub-study. And in those participants, semaglutide did something noteworthy. Here's another quote, In the CSF sub-study, Semaglutide led to significant reductions of up to ten percent in CSF-based core biomarkers associated with Alzheimer's disease, phosphorylated tau, non-phosphorylated tau, and CSF biomarkers of neuroinflammation, neurodegeneration, and synaptic function. Semaglutide treatment was also associated with significantly reduced plasma high-sensitivity C-reactive protein concentrations." Phosphorylated tau, neuroinflammation markers, synaptic function. The drug was moving the biological dials in the right direction. The underlying pathology was responding, but patients weren't getting any better at the level of day-to-day function and cognitive testing. Now, the gap between biomarker response and clinical response is, as of May 30th, 2026, going to be one of the most fascinating and frustrating questions in all of Alzheimer's research that is going to keep many scientists up in the middle of the night. It raises a series of questions that the field is now going to be very actively exploring and debating. When a trial this large and this well-designed fails to show clinical benefit, a good scientist does not shrug and move on. They ask, "Why?" And right now, there are at least three serious explanations that are worth investigating further. The first is that it's the wrong population, and this is, in my mind, the most compelling critique. The EVOKE study researchers acknowledged it directly. The authors wrote that the difference between the trial results and the encouraging real-world evidence could be explained by, and I quote, "Investigating the slowing of decline in a symptomatic Alzheimer's disease population rather than reduced Alzheimer's disease in a type two diabetes population." In other words, the initial Xu observational data showed GLP-1 drugs reduced the risk of getting Alzheimer's in people with existing metabolic disease. The trials tested whether GLP-1s could slow progression of Alzheimer's in people who had Alzheimer's, most of whom did not have significant metabolic disease. And that is a fundamentally different question. So let's think about this through the lens of Bredesen's subtypes. GLP-1 agonists like Ozempic address insulin resistance, neuroinflammation, and metabolic dysfunction, the mechanisms that drive type one inflammatory and type one point five glycotoxic subtypes. But the EVOKE trials enrolled everyone with confirmed amyloid pathology, regardless of the underlying driver at work. So someone with type three toxic Alzheimer's, driven by heavy metal exposure, who has no insulin resistance, would have zero reason to respond to a drug that targets insulin signaling. And someone with type four vascular Alzheimer's needs improved oxygen flow to the brain, not better glucose metabolism. If even twenty or thirty percent of this trial's population had the subtype that would actually respond to semaglutide and the rest didn't, that benefit in that population would be completely diluted out when looking at the group average, and the trial would read as a failure, even if the drug genuinely helped the right patients. Now, the second explanation is it's the wrong stage of disease pathology, right? Even among patients with metabolically-driven Alzheimer's disease, there is the very real question of timing. Real-world data shows reduced incidence when measuring prevention. It demonstrated semaglutide may be stopping people from getting the disease in the first place. The trial measured treatment, whether GLP-1 agonists could slow the disease after it had already taken hold. Now, by the time we show symptoms of Alzheimer's pathology, amyloid plaques have been established, tau tangles have been formed, synaptic connections have started to become lost, and removing the metabolic insult that triggered the cascade may not alone reverse structural damage. The window for intervention may have already closed. This is the same thing that we see in cardiovascular disease. Improving diet and metabolic health prevents atherosclerosis, but it's far less clear that it can actually reverse coronary artery disease that's been building for decades. Now, the third explanation is the wrong drug form or the wrong dose because the EVOKE trials used oral semaglutide at 14 milligrams. That's a tablet that you take. Now, that's the same dose used for type 2 diabetes, but oral availability of semaglutide is a lot lower than the injectable form, and that's part of the reason why the injectable form is the one we all know about. Only a small fraction of the oral dose actually gets into systemic circulation. So researchers are now asking whether a higher dose of the oral form or an injectable formulation may have produced different results in this study. And it's not a trivial point. The CSF sub-study found that the oral semaglutide was present in the cerebrospinal fluid, confirming it does cross the blood-brain barrier. But we don't know what concentration, and is that concentration enough to drive meaningful protection over the long haul? We still don't have answers to that, and I'm pretty damn sure there's gonna be some researchers looking at those questions specifically. So despite what on its face appears to be another epic failure of a drug trial, not everyone is walking away from GLP-1 agonists as a potential tool in Alzheimer's treatment. The scientific conversation that has emerged from the EVOKE trials may actually be more valuable to the scientific community than a positive trial would've been because it's forcing us to ask some long overdue questions about how we design and interpret Alzheimer's research. In my opinion, GLP-1s are likely going to be a fantastic tool for preventing Alzheimer's in those who have type 2 diabetes. Given that their risk of developing Alzheimer's may be upwards of 65% over someone who does not have type 2 diabetes, this can potentially prevent tens of millions of people from ever being diagnosed. Whether or not that reduction in Alzheimer's pathology can lead to improved cognition over time is something I'm actually super curious to see unfold. If we can remove those obstacles while also reducing the inflammation that led to their development, the brain could have a genuine chance to heal, and that would be the key difference between what previous tau and amyloid plaque-reducing drugs could do versus what a semaglutide can do. However, even if I'm right, that still leaves those without metabolic disease at risk. So I'm hoping that this trial opens the door for us to start viewing Alzheimer's disease like we now view cancer, not as a single disease to be eradicated, but as a disease with many possible causes that necessitates a more nuanced and targeted approach. Alzheimer's research is arguably where cancer research was in the 1980s. We're still mostly treating it as one disease when it may be five or six. We're still designing trials that lump everyone with amyloid in their brain into one group, regardless of why the amyloid got there in the first place. Now remember that Cleveland Clinic real-world data published in fall of 2025 still supports GLP-1 agonists as being associated with reduced Alzheimer's risk diagnoses, especially in metabolically compromised patients. That signal did not disappear. It just has not translated into a clinical benefit for a broad, diverse trial population. So the next logical step is to run a more targeted clinical trial, one that selects specifically for patients with the metabolic subtype one or one point five that are in early stages of cognitive decline. These are people who have both confirmed Alzheimer's pathology and evidence of insulin resistance, elevated inflammation, or metabolic dysfunction. Give the drug to a population where the mechanism of action makes sense. I also think, based upon Bredesen's line of thinking, that going back to hormone replacement therapy in the initial years of menopause is going to change the outcome for millions of women in my generation Who are watching their mothers and grandmothers denied hormones suffer from dementia in the last decade of their lives. If it hasn't touched us personally, we all have a friend who has a parent or grandparent with dementia. Now, remember Bredesen's type three, the atrophic, the lack of hormones that preserve brain health. As any woman going through perimenopause and struggling with brain fog can tell you, our sex hormones definitely impact our cognition. It remains to be seen if HRT will be preventative, but many Generation X women and elder millennials are now fully on board to not have to deal with the hell of perimenopause unassisted, and they will likely be better off in the long run, especially if we consider how our grandmothers and our great-grandmothers who were put on hormones after menopause in the 1960s and 1970s fared compared to how their daughters are doing today. It is a speculative leap to be sure, but given what we now are talking about with regards to hormone replacement therapy and preserved bone density and heart health in post-menopausal women, I don't think it's an irresponsibly speculative leap There are a lot of valuable takeaways from this research. First, if you're currently taking semaglutide for diabetes or weight management, don't assume that you are getting brain protection. The EVOKE results don't support that claim in people who already have symptomatic Alzheimer's. The preventative signal in those who are metabolically compromised is still interesting, but it is also still unproven at the level of a controlled trial. Second, the concept of Alzheimer's subtypes is super useful for thinking about your own personal risk. If you have a family history, if you carry the ApoE4 gene, if you also have insulin resistance or chronic inflammation, that cluster of risk factors is worth taking seriously and discussing with your doctor. The glycotoxic pathway is one you can do something about. Addressing blood sugar regulation, insulin sensitivity, inflammation, this is all within your control to have positive impacts. Diet, exercise, sleep management, all of those move the dial, and that's what I work with people on every single day. Third, the biomarker findings from the EVOKE study are really intriguing. Semaglutide reduced p-tau and neuroinflammation markers in that spinal fluid, even in the absence of clinical benefit. What that means is not fully clear, but it does suggest the drug is doing something biologically meaningful in the brain. Whether that translates to protection in the right population at a meaningful level is an open and actively studied question at this time. And fourth, and perhaps most importantly, this is a good moment to push back on our cultural tendency to want one answer, one drug, one magic bullet for a disease this complex. Alzheimer's likely is not one disease, and the solution probably isn't going to be one drug. What Bredesen's framework offers, regardless of your view of his specific protocol, is a useful corrective to that reductionistic thinking. The brain fails for reasons, and understanding those reasons and which ones you are most susceptible to is the beginning of a personalized strategy. So, are GLP-1 agonists ever going to be a successful Alzheimer's drug? That's going to depend on how we define success, first of all. I do think the signals of prevention are loud enough, and they're well-backed by what we know mechanistically. And so I do believe that GLP-1 medications can prevent millions of diabetics from ever developing Alzheimer's. I'm less excited about it as a treatment when the foundation has already been laid. I suspect that an injectable GLP-1 would show greater reductions in Alzheimer's biomarkers, and that might be enough to be clinically meaningful to those who are in early stages of decline. I'm less confident about oral semaglutide, particularly with increasing the dose to get a response simply because of side effects. And honestly, here is my bias on full display, folks. Without additional intentional re-nourishment of a brain depleted of glucose and nutrients for decades beforehand, I'm not confident that simply removing the irritant is gonna be enough. Replenishment needs to be part of the conversation, and that's not happening yet. Semaglutide may halt further decline, but without attention to nourishment, restoration of lost cognition seems dubious at best. I've talked about what it means and what it takes to re-nourish the brain in several other episodes of Blasphemous Nutrition. I'll link to those in the show notes, so you can take a look if that's something that interests you. But regardless, the EVOKE trials are now prompting us to ask better questions. And that, my friends, is how good science works. Thank you so much for listening to Blasphemous Nutrition, and a special, special thank you to Michelle, who reached out to ask me about the research on this topic. If this episode was useful for you, please share it with someone you know who is thinking about brain health. It's a conversation worth having. Citations and sources for research presented in this episode can be found on my Substack, which is also gonna be linked in the show notes. And until next time, remember, Ozempic can't fix everything, but all hope here is not lost. The brain is complicated, the science is messy, and anyone who tells you otherwise is probably selling something stupid. Stay curious and keep asking questions. Any and all information shared here is for educational and entertainment purposes only, and is not to be misconstrued as offering medical advice. Listening to this podcast does not constitute a provider-client relationship. Note, I'm not a doctor nor a nurse, and it is imperative that you utilize your brain and your medical team to make the best decisions for your own health. The use of information on this podcast or materials linked to this podcast are at the user's own risk. No information nor resources provided are intended to be a substitute for professional medical advice, diagnosis, or treatment. Be a smart human and do not disregard or postpone obtaining medical advice for any medical condition you may have. Seek the assistance of your healthcare team for any such conditions and always do so before making any changes to your medical, nutrition, or health plan If you have found some nuggets of wisdom, make sure to subscribe, rate, and share Blasphemous Nutrition with those you care about. As you navigate the labyrinth of health advice out there, remember, health is a journey, not a dietary dictatorship. Stay skeptical, stay daring, and challenge the norms that no longer serve you. If you've got burning questions or wanna share your own flavor of rebellion, slide into my DMs. Your stories fuel me, and I love hearing them. Thanks again for tuning into Blasphemous Nutrition. Until next time, this is Amy signing off, reminding you that truth is nuanced and any dish can be made better with a little bit of sass